RAD51C and neoplasm: Interestingly, RAD51C promoter was almost ubiquitously methylated in CIMP+ stomach cancer cases, but mostly at low tumour methylation level (likely heterozygous), suggesting that homozygous RAD51C methylation may offer a growth disadvantage in the stomach cancer development.